依那普利辅助治疗慢性肺心病

Enalapril in supportive treatment of chronic pulmonary heart disease

目的：探讨依那普利辅助治疗慢性肺心病的疗效。方法：慢性肺心病９８例，分为２组，依那普利组５８例（男性３１例，女性２７例；年龄６２±ｓ８ａ），给依那普利２．５ｍｇ，ｐｏ，ｔｉｄ，加常规疗法（头孢唑林３ｇ，ｉｖ，ｇｔ，ｂｉｄ；阿米卡星０．４ｇ，ｉｖ，ｇｔ，ｑｄ；氨茶碱０．１ｇ，ｐｏ，ｔｉｄ）。对照组４０例（男性２１例，女性１９例；年龄６３±７ａ）仅给常规疗法（用法同上）。２组疗程均２ｗｋ。结果：依那普利组治疗后ＣＩ，ＥＦ，ＣＯ，ＳＶ，ＦＶＣ，ＦＥＶ１，ＭＭＦ，ＰＥＦ，Ｐａｏ２，Ｐａｃｏ２，ＲＶＤ，ＲＶＯＴ改善较治疗前及对照组有显著差异（Ｐ＜０．０５或＜０．０１）。依那普利组临床总有效率９７％，显著高于对照组（８０％）（Ｐ＜０．０１），且不良反应少。结论：依那普利辅助治疗慢性肺心病疗效佳。

AIM: To probe the effect of supportive treatment of pulmonary heart disease with enalapril. METHODS: Enalapril group 58 patients (M 31, F 27; age 62±s 8 a) and control group 40 patients (M 21, F 19; age 63±7 a) all patients received cefazolin 3.0 g, iv, gtt, bid, amikacin 0.4 g, iv, gtt, qd and aminophylline 0.1 g, po, tid were routine therapy , former group were given whereas latter group were not given, enalapril 2.5 mg, po tid, 2 groups patients received 2 wk treatments make a course. RESULTS: Showed that CI, EF, CO, SV, FVC, FEV 1, MMF, PEF, Pao 2,Paco 2, RVD and RVOT in the enalapril group after treatment were improving higher than those in the enalapril before treatment and those in the control group (P<0.05 or< 0.01). The total clinical response rate in the enalapril group (97%) was higher than that in the control group (80%) Adverse reactions were mild. CONCLUSION: Enalapril is a good drug for supportive treatment of pulmonary heart disease.